Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy Virtual 2020 | Treating MM patients in the COVID-19 era

Meral Beksac • 13 May 2020
COMy Virtual 2020
Multiple Myeloma Lenalidomide

Meral Beksac, MD, Ankara University, Ankara, Turkey, sheds light on the management of multiple myeloma (MM) patients during the COVID-19 pandemic. Dr Beksac discusses some of the most challenging cases and reveals that patients should continue their therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Meral Beksac

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Guidance on managing ocular toxicities associated with belantamab mafodotin in multiple myeloma
1:38
Guidance on managing ocular toxicities associated with belantamab mafodotin in multiple myeloma
Meral Beksac • 17 Sep 2025
Improving CAR T-cell responsiveness and overcoming resistance in multiple myeloma
3:02
Improving CAR T-cell responsiveness and overcoming resistance in multiple myeloma
Meral Beksac • 17 Sep 2025
Strategies to enhance the efficacy of CAR T-cell therapy in multiple myeloma
1:56
Strategies to enhance the efficacy of CAR T-cell therapy in multiple myeloma
Meral Beksac • 17 Sep 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Meral Beksac • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Meral Beksac • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Meral Beksac • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Meral Beksac • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals